β2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 1, 2012, Pages 206-218

  Murray, David R ^a   Mummidi, Srinivas ^b,c   Valente, Anthony J ^b,c   Yoshida, Tadashi ^d   Somanna, Naveen K ^d   Delafontaine, Patrice ^d   Dinarello, Charles A ^e   Chandrasekar, Bysani ^c,d  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenergic stimulation; Cloning; Heart failure; Molecular mechanism; Signal transduction; Transcription

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; INTERLEUKIN 18; ISOPRENALINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTRALIZING ANTIBODY; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; GENE ACTIVITY; GENE DELETION; GENE MUTATION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN MOTIF; STEADY STATE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; CARDIOMEGALY; CCAAT-ENHANCER-BINDING PROTEINS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GENE EXPRESSION REGULATION; GENE KNOCKOUT TECHNIQUES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-18; ISOPROTERENOL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCYTES, CARDIAC; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

MUS MUSCULUS;

EID: 84155180926     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.09.022     Document Type: Article

References (42)

1. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res Nov 29 2002, 91(11):988-998.
2. Mann D.L. Targeted anticytokine therapy and the failing heart. Am J Cardiol Jun 6 2005, 95(11A):9C-16C. discussion 38C-40C.
3. Nakano M., Knowlton A.A., Dibbs Z., Mann D.L. Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation Apr 14 1998, 97(14):1392-1400.
4. Dinarello C.A., Novick D., Puren A.J., Fantuzzi G., Shapiro L., Muhl H., et al. Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol Jun 1998, 63(6):658-664.
5. Mallat Z., Heymes C., Corbaz A., Logeart D., Alouani S., Cohen-Solal A., et al. Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure. FASEB J Nov 2004, 18(14):1752-1754.
6. Seta Y., Kanda T., Tanaka T., Arai M., Sekiguchi K., Yokoyama T., et al. Interleukin-18 in patients with congestive heart failure: induction of atrial natriuretic peptide gene expression. Res Commun Mol Pathol Pharmacol 2000, 108(1-2):87-95.
7. Kim S.H., Eisenstein M., Reznikov L., Fantuzzi G., Novick D., Rubinstein M., et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A 2000, 97(3):1190-1195.
8. Ten Hove T., Corbaz A., Amitai H., Aloni S., Belzer I., Graber P., et al. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology 2001, 121(6):1372-1379.
9. Faggioni R., Cattley R.C., Guo J., Flores S., Brown H., Qi M., et al. IL-18-binding protein protects against lipopolysaccharide- induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice. J Immunol 2001, 167(10):5913-5920.
10. Chandrasekar B., Mummidi S., Claycomb W.C., Mestril R., Nemer M. Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J Biol Chem 2005, 280(6):4553-4567.
11. Majumdar G., Johnson I.M., Kale S., Raghow R. Epigenetic regulation of cardiac muscle-specific genes in H9c2 cells by Interleukin-18 and histone deacetylase inhibitor m-carboxycinnamic acid bis-hydroxamide. Mol Cell Biochem 2008, 312(1-2):47-60.
12. Platis A., Yu Q., Moore D., Khojeini E., Tsau P., Larson D. The effect of daily administration of IL-18 on cardiac structure and function. Perfusion 2008, 23(4):237-242.
13. Woldbaek P.R., Sande J.B., Stromme T.A., Lunde P.K., Djurovic S., Lyberg T., et al. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am J Physiol Heart Circ Physiol 2005, 289(2):H708-H714.
14. Colston J.T., Boylston W.H., Feldman M.D., Jenkinson C.P., de la Rosa S.D., Barton A., et al. Interleukin-18 knockout mice display maladaptive cardiac hypertrophy in response to pressure overload. Biochem Biophys Res Commun 2007, 354(2):552-558.
15. Chandrasekar B., Marelli-Berg F.M., Tone M., Bysani S., Prabhu S.D., Murray D.R. Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB. Biochem Biophys Res Commun 2004, 319(2):304-311.
16. Fantuzzi G., Banda N.K., Guthridge C., Vondracek A., Kim S.H., Siegmund B., et al. Generation and characterization of mice transgenic for human IL-18-binding protein isoform a. J Leukoc Biol 2003, 74(5):889-896.
17. Shanmugam P., Valente A.J., Prabhu S.D., Venkatesan B., Yoshida T., Delafontaine P., et al. Angiotensin-II type 1 receptor and NOX2 mediate TCF/LEF and CREB dependent WISP1 induction and cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2011, 50(6):928-938.
18. Reddy V.S., Prabhu S.D., Mummidi S., Valente A.J., Venkatesan B., Shanmugam P., et al. Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation. Am J Physiol Heart Circ Physiol. 2010, 299(4):H1242-H1254.
19. Smeets R.L., van de Loo F.A., Arntz O.J., Bennink M.B., Joosten L.A., van den Berg W.B. Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther 2003, 10(12):1004-1011.
20. Morisco C., Zebrowski D.C., Vatner D.E., Vatner S.F., Sadoshima J. Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart. J Mol Cell Cardiol 2001, 33(3):561-573.
21. Du K., Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem Dec 4 1998, 273(49):32377-32379.
22. Morisco C., Zebrowski D., Condorelli G., Tsichlis P., Vatner S.F., Sadoshima J. The Akt-glycogen synthase kinase 3beta pathway regulates transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation in cardiac myocytes. J Biol Chem May 12 2000, 275(19):14466-14475.
23. Venkatesan B, Prabhu SD, Venkatachalam K, Mummidi S, Valente AJ, Clark RA, et al. WNT1-inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks doxorubicin-induced cardiomyocyte death. Cell Signal. May; 22(5): 809-20.
24. Bristow M.R. beta-adrenergic receptor blockade in chronic heart failure. Circulation Feb 8 2000, 101(5):558-569.
25. Daaka Y., Luttrell L.M., Lefkowitz R.J. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature Nov 6 1997, 390(6655):88-91.
26. Perry S.J., Baillie G.S., Kohout T.A., McPhee I., Magiera M.M., Ang K.L., et al. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science Oct 25 2002, 298(5594):834-836.
27. Mialet-Perez J., Green S.A., Miller W.E., Liggett S.B. A primate-dominant third glycosylation site of the beta2-adrenergic receptor routes receptors to degradation during agonist regulation. J Biol Chem Sep 10 2004, 279(37):38603-38607.
28. Ferguson S.S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev Mar 2001, 53(1):1-24.
29. Hurgin V., Novick D., Rubinstein M. The promoter of IL-18 binding protein: activation by an IFN-gamma -induced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein beta. Proc Natl Acad Sci U S A Dec 24 2002, 99(26):16957-16962.
30. Niehof M., Manns M.P., Trautwein C. CREB controls LAP/C/EBP beta transcription. Mol Cell Biol Jul 1997, 17(7):3600-3613.
31. Cornelius T., Holmer S.R., Muller F.U., Riegger G.A., Schunkert H. Regulation of the rat atrial natriuretic peptide gene after acute imposition of left ventricular pressure overload. Hypertension Dec 1997, 30(6):1348-1355.
32. Collins S., Altschmied J., Herbsman O., Caron M.G., Mellon P.L., Lefkowitz R.J. A cAMP response element in the beta 2-adrenergic receptor gene confers transcriptional autoregulation by cAMP. J Biol Chem Nov 5 1990, 265(31):19330-19335.
33. Parry G.C., Mackman N. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. J Immunol Dec 1 1997, 159(11):5450-5456.
34. Zhong H., Voll R.E., Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell Apr 1998, 1(5):661-671.
35. Marotte H., Ahmed S., Ruth J.H., Koch A.E. Blocking ERK-1/2 reduces tumor necrosis factor alpha-induced interleukin-18 bioactivity in rheumatoid arthritis synovial fibroblasts by induction of interleukin-18 binding protein A. Arthritis Rheum. Mar 2010, 62(3):722-731.
36. Stein B., Cogswell P.C., Baldwin A.S. Functional and physical associations between NF-kappa B and C/EBP family members: a Rel domain-bZIP interaction. Mol Cell Biol Jul 1993, 13(7):3964-3974.
37. Matsusaka T., Fujikawa K., Nishio Y., Mukaida N., Matsushima K., Kishimoto T., et al. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A Nov 1 1993, 90(21):10193-10197.
38. Kunsch C., Lang R.K., Rosen C.A., Shannon M.F. Synergistic transcriptional activation of the IL-8 gene by NF-kappa B p65 (RelA) and NF-IL-6. J Immunol Jul 1 1994, 153(1):153-164.
39. Flesch M. On the trail of cardiac specific transcription factors. Cardiovasc Res Apr 2001, 50(1):3-6.
40. Han I., Kudlow J.E. Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol May 1997, 17(5):2550-2558.
41. Murray D.R., Prabhu S.D., Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation May 23 2000, 101(20):2338-2341.
42. Prabhu S.D., Chandrasekar B., Murray D.R., Freeman G.L. beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation May 2 2000, 101(17):2103-2109.